Event-Free Survival as a Predictor of Overall Survival and Recurrence Burden of Patients with Non-Small Cell Lung Cancer Receiving Neoadjuvant Therapy.

Event-free survival (EFS) has replaced overall survival (OS) as a primary endpoint in many recent and on-going clinical trials. This study aims to examine the correlation between real-world EFS (rwEFS) and OS and to assess the clinical and economic burden associated with disease recurrence among patients with resected, stage II-III non-small cell lung cancer (NSCLC) received neoadjuvant therapy in the US. This retrospective study used the SEER-Medicare database (2007-2019) to identify patients with newly diagnosed, resected, stage II-IIIB (N2) NSCLC received neoadjuvant therapy. The correlation between rwEFS and OS was assessed using the normal scores rank correlation and landmark analysis. OS, all-cause healthcare resource utilization (HCRU) and costs, and NSCLC-related HCRU and costs were compared between patients with and without recurrence. A total of 221 patients met the eligibility criteria (median follow-up time from neoadjuvant treatment initiation: 32.7 months). The mean age was 72.1 years, and 57.0% of patients were male. rwEFS and OS are positively and significantly correlated (0.68; 95% CI: 0.52-0.79). Patients with recurrence had significantly shorter median OS (19.3 months vs. 116.9 months), 4.59 times increased risk of death (95% CI: 2.56, 8.26), and significantly higher all-cause and NSCLC-related HCRU and costs (adjusted mean monthly costs per patient difference: $5,758 and $3,187, respectively (all p<0.001). These findings help validate EFS as a clinically meaningful endpoint and strong predictor for OS and highlight the need for additional novel therapies that may delay or prevent recurrence in resectable stage II and III NSCLC.

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.